PubRank

Lode J Swinnen

Author PubWeight™ 30.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010 2.17
2 Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 2009 2.09
3 Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003 1.88
4 Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leuk Lymphoma 2012 1.57
5 Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 2013 1.51
6 High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leuk Lymphoma 2011 1.49
7 Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012 1.23
8 Epstein-Barr Virus (EBV) DNA in plasma is not encapsidated in patients with EBV-related malignancies. Diagn Mol Pathol 2004 1.22
9 Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw 2014 1.17
10 Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013 1.13
11 Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol 2005 1.11
12 Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant 2009 1.10
13 An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol 2002 1.10
14 Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2011 1.06
15 Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw 2014 0.94
16 Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer 2006 0.93
17 FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy. Curr Opin Oncol 2004 0.90
18 Treatment advances in adult Burkitt lymphoma and leukemia. Curr Opin Oncol 2004 0.90
19 Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Netw 2016 0.89
20 Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant 2007 0.88
21 Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation 2006 0.88
22 Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2013 0.87
23 Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Leuk Lymphoma 2011 0.83
24 Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation 2003 0.81
25 Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw 2015 0.81
26 Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2011 0.79
27 Conservation of Epstein-Barr virus cytotoxic T-cell epitopes in posttransplant lymphomas: implications for immune therapy. Am J Pathol 2002 0.78
28 Early treatment intensification for aggressive non-Hodgkin's lymphoma. Curr Opin Oncol 2006 0.75